Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
Patients with a history of idiopathic gastroduodenal ulcer bleeding face an increased risk of
recurrent ulcer gastrointestinal bleeding. Our ongoing clinical trial demonstrates a possible
reduced risk of recurrent idiopathic gastroduodenal ulcer bleeding with proton pump inhibitor
(PPI), yet there is a significant risk of recurrent ulcer bleeding as PPI may increase the
risk of small bowel bleeding. Our preliminary data provide strong plausibility that a
combination therapy of misoprostol (MISO) with a PPI reduces the recurrent ulcer bleeding as
well as clinical gastrointestinal bleeding. The investigators are going to provide the
definitive answer to this important clinical question through a randomised trial.